Pharmacogenomic genome-wide association studies: lessons learned thus far.
about
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle DisordersGenotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*DProgress towards the integration of pharmacogenomics in practiceSystems biology of human benzene exposure.An integrative method for scoring candidate genes from association studies: application to warfarin dosing.Implementation and utilization of genetic testing in personalized medicine.Genome-wide association studies in pharmacogenomics: successes and lessons.Joint GWAS Analysis: Comparing similar GWAS at different genomic resolutions identifies novel pathway associations with six complex diseases.Personalizing medicine with clinical pharmacogeneticsIntegrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription ProfilingPersonalised medicine in paediatrics: individualising treatment in children with rare neurological diseases.Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.Genome-wide association studies in pharmacogenomics: untapped potential for translationPediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.Pharmacogenetic Biomarkers to Predict Treatment Response in Multiple Sclerosis: Current and Future Perspectives.The public health utility of genome-wide association study results for smoking behavior.Pharmacogenomics and bioinformatics: PharmGKB.Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Ask the experts: pharmacogenomics and genome-wide association studies.Personalized therapy and pharmacogenomics: future perspective
P2860
Q26753129-2D7113C9-4CA3-4BC8-8D4B-1F623337F1AAQ28486019-D0D4FF0A-3E53-47F9-B7C1-8FEA22FE8306Q28652270-B9E336AD-577D-40A4-BF45-796400C8CDD0Q33755957-FAD21FFA-58F4-4450-8AC3-6D1C3B3F9561Q34147587-2E9F34BF-317C-4894-B508-AD799FBF4329Q34147916-BBC12195-AC69-4D2E-A92C-0D5227075BD3Q34415006-121CA99C-BC05-481D-842A-E024959A2444Q35229857-3774AE69-9E92-4359-AE3C-03272EB9F614Q35791989-4E05E9D7-5E0A-433E-A14A-7DEF75AD7061Q35799611-E9EC8FE1-A181-4CB4-A400-54262E4CD412Q36117928-0E4E80BE-0F6D-4C1F-9A69-8CF84FCD85F4Q36817242-32CE68DA-F788-4D71-BCD6-4F38DE0E7511Q37198455-C97823ED-8A3B-4A09-8BDA-0B063C23B624Q37808658-20D5B784-431E-4537-911D-BA2C899B7CEAQ38643129-9E94D6A8-5A62-4C5C-922C-13E16CC483CCQ40663971-0D78FAE7-AE9C-401C-833E-CA73C64E125AQ42654621-08EF82BA-54CD-463C-BCAA-CA6504738872Q43986380-A2A2BBA5-6846-4FC1-9104-1EE7EAEA7355Q44208517-DB4D83EB-5BEE-4C8E-833D-ECDF96219DCCQ44936222-AFDBFF67-8130-4107-8B5D-55244A078D2DQ45007058-B603259E-AB5B-4E5A-8A2B-BAC4ABB11C6CQ46676771-5EC103B1-9B2F-42BB-8FD1-07FB009502A0Q57994790-B439B5AF-1482-47D8-9CCE-55E733AAA32B
P2860
Pharmacogenomic genome-wide association studies: lessons learned thus far.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Pharmacogenomic genome-wide association studies: lessons learned thus far.
@en
type
label
Pharmacogenomic genome-wide association studies: lessons learned thus far.
@en
prefLabel
Pharmacogenomic genome-wide association studies: lessons learned thus far.
@en
P2860
P1433
P1476
Pharmacogenomic genome-wide association studies: lessons learned thus far
@en
P2093
Howard L McLeod
Patrick F Sullivan
P2860
P304
P356
10.2217/14622416.10.2.161
P577
2009-02-01T00:00:00Z